Leukemia Therapeutics Global Market Report 2025

Description

Leukemia therapeutics refer to treatments used to address an aggressive malignancy characterized by an excessive presence of myeloblasts, immature white blood cells, in the blood or bone marrow. The choice of treatment for leukemia depends on factors such as age, overall health, the specific type of leukemia, its current state within the body, and other relevant considerations.

The primary types of treatments in leukemia therapeutics include chemotherapy, immunotherapy, targeted therapy, and other specific treatments. Immunotherapy involves stimulating the body's immune system to recognize and eliminate malignant cells. This approach is applied to treat various types of leukemia, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, using both small molecules and biologics. End users of leukemia therapeutics include hospitals, homecare settings, specialty clinics, and other relevant healthcare providers.

The leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. This leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukemia therapeutics market size has grown strongly in recent years. It will grow from $17.57 billion in 2024 to $18.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to growth in geriatric population, improved diagnostics leading to early detection of leukemia, increasing prevalence of leukemia, growing investment in research and development, expansion of personalized medicine approaches.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $25.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to development of novel immunotherapies for leukemia, growing focus on precision medicine in leukemia treatment, expansion of indications for existing leukemia therapies, increased adoption of gene therapies, advances in supportive care for leukemia patients. Major trends in the forecast period include integration of biomarker-driven approaches, rise of combination therapies for enhanced efficacy, emphasis on minimal residual disease monitoring, increasing use of car-t cell therapies, exploration of targeted therapies based on leukemia subtypes.

The leukemia therapeutics market is experiencing growth driven by the increasing prevalence of leukemia, a type of blood cancer characterized by uncontrolled blood cell growth originating in the bone marrow. The global accessibility of medical treatment for leukemia patients and the expanding array of treatment options contribute to the growing demand for leukemia therapeutics. As of January 2023, the American Cancer Society projects around 59,610 new cases of leukemia and approximately 23,710 leukemia-related deaths in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and approximately 11,310 AML-related deaths are expected in the same year. Thus, the escalating incidence of leukemia is a significant factor propelling the growth of the leukemia therapeutics market.

The growth of the geriatric population is anticipated to further fuel the expansion of the leukemia therapeutics market. The term 'geriatric population' pertains to individuals aged 65 and older. With the aging of the population, the heightened risk of developing leukemia and related blood disorders increases, leading to a greater demand for leukemia therapeutics. According to a report by the World Health Organization (WHO) in October 2022, it is projected that one in six people globally will be 60 or older by 2030, and by 2050, the worldwide population of individuals aged 60 and older will reach 2. 1 billion. Consequently, the rise in the geriatric population serves as a driving force for the growth of the leukemia therapeutics market.

Major companies in the leukemia therapeutics market are embracing a strategic partnership approach to facilitate the launch and commercialization of their first advanced cancer treatment in the United States. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For instance, in February 2023, Xspray Pharma AB, a Sweden-based biotechnology firm, partnered with EVERSANA, a US-based company that provides commercial services to the life sciences industry. This collaboration aims to support the U.S. launch and commercialization of Xspray's first innovative cancer therapy, Dasynoc, which is intended for treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Under this agreement, Xspray Pharma will maintain financial and strategic control while granting EVERSANA exclusive commercialization rights to aid in the Dasynoc launch, scheduled for the second half of 2023.

Major companies in the leukemia therapeutics market are focusing on developing innovative products, such as CAR-T therapies, to reach larger customer bases, boost sales, and increase revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a revolutionary approach to immunotherapy for treating certain types of cancer. For example, in March 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Breyanzi (lisocabtagene maraleucel; liso-cel). This therapy is a CD19-directed CAR-T cell treatment specifically designed for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already undergone at least two previous lines of therapy, which must include both a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition strengthens AstraZeneca's growing pipeline of cell therapies by incorporating GC012F, a novel clinical-stage FasTCAR-enabled autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets both BCMA and CD19. Gracell will operate as a wholly owned subsidiary of AstraZeneca, continuing its activities in both China and the United States. Gracell Biotechnologies Inc. is a China-based biopharmaceutical company specializing in cell therapies for leukemia and autoimmune diseases.

Major companies operating in the leukemia therapeutics market include Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the leukemia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The leukemia therapeutics market includes revenues earned by entities by by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leukemia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leukemia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leukemia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leukemia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Therapy; Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Other Type Of Leukemia
3) By Molecule Type: Small Molecules; Biologics
4) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Plant Alkaloids; Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies; CAR T-Cell Therapy; Immune Checkpoint Inhibitors; Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); BCL-2 Inhibitors; IDH Inhibitors; Other Targeted Agents
4) By Other Treatments: Radiation Therapy; Stem Cell Transplantation; Supportive Care Treatments
Companies Mentioned: Novartis International AG; AbbVie Inc.; Bristol Myers Squibb Company; F. Hoffmann-La Roche AG; Sanofi S. A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r21711

1. Executive Summary

2. Leukemia Therapeutics Market Characteristics

3. Leukemia Therapeutics Market Trends And Strategies

4. Leukemia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Leukemia Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Leukemia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Leukemia Therapeutics Market Growth Rate Analysis
5.4. Global Leukemia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Leukemia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Leukemia Therapeutics Total Addressable Market (TAM)

6. Leukemia Therapeutics Market Segmentation

6.1. Global Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Targeted Therapy
Other Treatments
6.2. Global Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Other Type Of Leukemia
6.3. Global Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecules
Biologics
6.4. Global Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.5. Global Leukemia Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alkylating Agents
Antimetabolites
Plant Alkaloids
Corticosteroids
6.6. Global Leukemia Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
CAR T-Cell Therapy
Immune Checkpoint Inhibitors
Vaccines
6.7. Global Leukemia Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors (TKIs)
BCL-2 Inhibitors
IDH Inhibitors
Other Targeted Agents
6.8. Global Leukemia Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Radiation Therapy
Stem Cell Transplantation
Supportive Care Treatments

7. Leukemia Therapeutics Market Regional And Country Analysis

7.1. Global Leukemia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Leukemia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leukemia Therapeutics Market

8.1. Asia-Pacific Leukemia Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leukemia Therapeutics Market

9.1. China Leukemia Therapeutics Market Overview
9.2. China Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leukemia Therapeutics Market

10.1. India Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leukemia Therapeutics Market

11.1. Japan Leukemia Therapeutics Market Overview
11.2. Japan Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leukemia Therapeutics Market

12.1. Australia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leukemia Therapeutics Market

13.1. Indonesia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leukemia Therapeutics Market

14.1. South Korea Leukemia Therapeutics Market Overview
14.2. South Korea Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leukemia Therapeutics Market

15.1. Western Europe Leukemia Therapeutics Market Overview
15.2. Western Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leukemia Therapeutics Market

16.1. UK Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leukemia Therapeutics Market

17.1. Germany Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leukemia Therapeutics Market

18.1. France Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leukemia Therapeutics Market

19.1. Italy Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leukemia Therapeutics Market

20.1. Spain Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leukemia Therapeutics Market

21.1. Eastern Europe Leukemia Therapeutics Market Overview
21.2. Eastern Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leukemia Therapeutics Market

22.1. Russia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leukemia Therapeutics Market

23.1. North America Leukemia Therapeutics Market Overview
23.2. North America Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leukemia Therapeutics Market

24.1. USA Leukemia Therapeutics Market Overview
24.2. USA Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leukemia Therapeutics Market

25.1. Canada Leukemia Therapeutics Market Overview
25.2. Canada Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leukemia Therapeutics Market

26.1. South America Leukemia Therapeutics Market Overview
26.2. South America Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leukemia Therapeutics Market

27.1. Brazil Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leukemia Therapeutics Market

28.1. Middle East Leukemia Therapeutics Market Overview
28.2. Middle East Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leukemia Therapeutics Market

29.1. Africa Leukemia Therapeutics Market Overview
29.2. Africa Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leukemia Therapeutics Market Competitive Landscape And Company Profiles

30.1. Leukemia Therapeutics Market Competitive Landscape
30.2. Leukemia Therapeutics Market Company Profiles
- 30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis

31. Leukemia Therapeutics Market Other Major And Innovative Companies

31.1. Agios Pharmaceuticals
31.2. Amgen Inc.
31.3. Argenx SE
31.4. Astellas Pharma Inc.
31.5. BioLineRx Ltd.
31.6. Cellerant Therapeutics Inc.
31.7. Daiichi Sankyo Company Limited
31.8. Forma Therapeutics Inc.
31.9. Gilead Sciences Inc.
31.10. Incyte Corporation
31.11. Jazz Pharmaceuticals plc
31.12. Johnson & Johnson
31.13. Mirati Therapeutics Inc.
31.14. Molecular Templates Inc.
31.15. Ono Pharmaceutical Co. Ltd.

32. Global Leukemia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leukemia Therapeutics Market

34. Recent Developments In The Leukemia Therapeutics Market

35. Leukemia Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Leukemia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Leukemia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Leukemia Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer